NCT01465386终止2 期
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
详细描述
PRIMARY OBJECTIVES:
I. To determine if bortezomib when given as maintenance therapy for six months post-remission can improve the progression-free survival (PFS) rate by 50% (or 4.5 months) in first remission patients with high-risk AML.
SECONDARY OBJECTIVES:
I. To determine the overall survival (OS) after maintenance therapy with bortezomib in first remission AML patients.
II. To assess the safety and tolerability of subcutaneous (SC) administration of bortezomib given as maintenance therapy to first remission AML patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All adults with first remission AML including those with prior myelodysplasia (MDS)/AML, therapy-related AML, AML with trilineage dysplasia (AML-TLD), and AML with adverse cytogenetics
- •History of histopathologically documented AML that is currently in first remission with the presence of 5% or less blasts by morphology and/or flow cytometry from a bone marrow aspirate and/or biopsy obtained within 14 days of enrollment
- •Patients must start therapy between 3-8 weeks after receiving their last prior therapy (either induction therapy or consolidation therapy)
- •Patients may receive up to 4 courses of remission consolidation therapy (e.g., cytarabine) prior to enrollment
- •Normal kidney and liver function with serum creatinine =< 2.0 mg/dl
- •Total bilirubin =< 1.5 upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse
- •Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse
- •Understand and voluntarily sign the informed consent form for this study
排除标准
- •Favorable AML features defined as the following:
- •t(8;21)(q22;q22); RUNX1-RUNX1T1
- •inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
- •Mutated NPM1 without FLT3-ITD (normal karyotype)
- •Mutated CEBPA (normal karyotype)
- •Persistent clinically significant non-hematological toxicity that is > Grade 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4 from prior chemotherapy
- •Active uncontrolled infection
- •Known infection with human immunodeficiency virus (HIV)
- •Medical condition, serious concurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study
- •Uncontrolled or significant cardiovascular disease, including:
- •Uncontrolled angina or myocardial infarction within 6 months
- •Current or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless a screening echocardiogram (ECHO) or Multiple Gate Acquisition Scan (MUGA) performed within 1 month prior to study screening results in a left ventricular ejection fraction (LVEF) that is >= 45% (or institutional lower limit of normal value)
- •Prolonged QTc interval (> 450 msec)
- •Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
- •Patient has a platelet count of < 30,000 within 3 days before enrollment
- •Patient has an absolute neutrophil count of < 300 within 3 days before enrollment
- •Patient has >= Grade 2 peripheral neuropathy
- •Patient has hypersensitivity to bortezomib, boron, or mannitol
- •Female patients who are lactating or have a positive urine pregnancy test during the screening; pregnancy testing is not required for postmenopausal or surgically sterilized women
- •Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
研究组 & 干预措施
Treatment (enzyme inhibitor therapy)
Experimental
Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: bortezomib (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Up to 2 years
Number of days from enrollment to recurrence of acute myeloid leukemia as determined by the reappearance of blasts in the blood or marrow
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceMultiple MyelomaNCT01647165National Cancer Institute (NCI)
终止
2 期
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensMultiple MyelomaNCT01695330Oncotherapeutics5
已完成
2 期
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerAdenocarcinoma of the LungBronchoalveolar Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNon-small Cell Lung CancerNCT00118144National Cancer Institute (NCI)42
Unknown
2 期
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsOvarian Neoplasm EpithelialHigh Grade Serous CarcinomaNCT03509246Seoul National University Hospital44
进行中（未招募）
2 期
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN DeletionMetastatic Castration-resistant Prostate CancerNCT06029998University of Utah22